Loading
CRISPR and Genetic Engineering / Cancer Research and Treatments · Journal article
Genetics and Molecular Research · July 15, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes the molecular rationale and preclinical promise of CRISPR-Cas systems for targeting multidrug-resistant bacteria. The authors describe mechanistic advantages—selective elimination of resistant organisms, disruption of resistance genes, biofilm inhibition—and technological advances in delivery, but acknowledge major translational barriers including delivery efficiency, off-target effects, and lack of clinical validation. No human efficacy data, trial results, or quantitative outcomes are reported.
Narrative literature review.
CRISPR-enabled antimicrobial strategies demonstrate specificity by selectively eliminating MDR bacteria, disrupting resistance genes, targeting virulence factors, inhibiting biofilm formation, and restoring antibiotic susceptibility. Advances in bacteriophage-mediated delivery, nanoparticle carriers, RNA-targeting systems, and AI-assisted guide RNA design have expanded clinical potential. Significant translational barriers remain: delivery efficiency, off-target editing, bacterial escape mechanisms, biosafety, regulatory approval, and large-scale manufacturing.
No clinical trial data, human efficacy outcomes, or safety results reported. Significant translational barriers remain: delivery efficiency, off-target editing, bacterial escape mechanisms, biosafety, regulatory approval, and large-scale manufacturing.
This review outlines the theoretical framework and current technological status of CRISPR antimicrobials but does not provide evidence-based guidance for clinical adoption. Clinicians should regard CRISPR-enabled approaches as an emerging research direction requiring substantial further development and rigorous clinical validation before implementation in practice.
This is a narrative review synthesizing mechanistic and preclinical evidence on CRISPR antimicrobials; it raises the therapeutic potential of the platform but does not report original clinical data, RCT results, or human efficacy outcomes.
As stated by the source record.
This review outlines the theoretical framework and current technological status of CRISPR antimicrobials but does not provide evidence-based guidance for clinical adoption. Clinicians should regard CRISPR-enabled approaches as an emerging research direction requiring substantial further development and rigorous clinical validation before implementation in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Antimicrobial resistance (AMR) has become one of the most serious global public health threats, driven by the rapid emergence and dissemination of multidrug-resistant (MDR) pathogens. The declining effectiveness of conventional antibiotics necessitates the development of innovative therapeutic strategies capable of selectively targeting resistant microorganisms while preserving beneficial microbiota. CRISPR-Cas technology has emerged as a promising precision antimicrobial platform with the potential to transform infectious disease management. This review summarizes the molecular mechanisms, delivery platforms, therapeutic applications, emerging innovations, safety considerations, translational barriers, and future prospects of CRISPR-enabled antimicrobial strategies for combating MDR bacterial infections. This review evaluated recent peer-reviewed literature on CRISPR-Cas systems, AMR, genome editing, precision medicine, delivery technologies, and translational research. The available evidence was synthesized to assess current advances, therapeutic potential, existing limitations, and future opportunities for CRISPR-based antimicrobial interventions. CRISPR-enabled antimicrobial strategies demonstrate remarkable specificity by selectively eliminating multidrug-resistant bacteria, disrupting resistance genes, targeting virulence factors, inhibiting biofilm formation, and restoring antibiotic susceptibility. Advances in bacteriophage-mediated delivery, nanoparticle-based carriers, programmable RNA-targeting systems, artificial intelligence-assisted guide RNA design, synthetic biology, and personalized precision medicine have further expanded their clinical potential. Nevertheless, challenges related to delivery efficiency, off-target editing, bacterial escape mechanisms, biosafety, regulatory approval, and large-scale manufacturing remain significant translational barriers. Overall, CRISPR-based antimicrobial therapy represents a transformative approach to precision infectious disease management, with continued technological innovation, interdisciplinary collaboration, and robust clinical validation expected to facilitate its safe, effective, and clinically accessible implementation against multidrug-resistant pathogens.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.